Imagine if you could see a 'volume knob' for the part of your brain that triggers fear and anxiety. This technology uses a wearable cap to translate complex brain waves into a simple signal, allowing patients to practice turning that volume down themselves. It's like a gym for the brain that helps people with trauma regain control over their emotions without needing surgery or heavy medication.
Current PTSD treatments are often ineffective, expensive, and cause severe side effects. There is a massive gap in the €7.5B market for a non-invasive, affordable way to treat abnormal brain activity.
A digital therapeutic device (Prism) that uses EEG and machine learning to allow patients to self-control amygdala activity.
If you are a clinic dealing with patients who find current PTSD treatments marginal or too costly — this project developed a digital therapeutic device that allows patients to self-control abnormal brain activity. This provides a non-invasive alternative to traditional therapies.
If you are a provider dealing with the lack of effective digital tools for severe mental disorders — this project developed an EEG-Neurofeedback device that uses machine learning to mimic fMRI data. This enables high-precision brain training at a lower cost than hospital imaging.
If you are a company dealing with high rates of stress-related disorders in a global market estimated at €7.5B — this project developed a tool for stress-resilience. It helps employees manage brain-region activity to improve mental health outcomes.
The global market size for PTSD treatments is estimated at €7.5B.
Based on available project data, current treatments are described as costly, while this solution uses an affordable EEG-Neurofeedback device.
Yes, the project description explicitly mentions a patented innovation using proprietary models.
The project aims to reach TRL8 and is preparing for a commercial launch in the EU, starting in Germany, indicating a plan for industrial scale.
The project period runs from 2022-09-01 to 2025-05-31, with the objective of launching the product in the EU market within this window.
The project is led by a single Israeli SME, GrayMatters Health Ltd. This 100% industry-led structure suggests a strong focus on commercialization and rapid market entry rather than academic research, supported by founders with a track record of IPOs and exits.
Contact GrayMatters Health Ltd in Israel
Contact us to explore licensing opportunities for this PTSD neurofeedback technology.
